Male breast cancer is rare but still significant within the larger spectrum of breast cancer. The market for male breast cancer is receiving more attention as awareness is growing and diagnostic capabilities are improving in a number of ways. Breast cancer in men, traditionally considered predominantly a female condition, constitutes less than 1% of all incidences of the disease. Nonetheless, male patients affected by this condition need a lot of research targeted at them, specialized treatments and also heightening of awareness.
Lately there has been increasing recognition of unique features presented by the male breast cancer leading to increased levels of research and development activities targeting this particular patient population. Diagnostic procedures for male breast cancer market have improved especially with the introduction such genetic tests as DNA tests to identify vulnerable individuals. These innovations enable early detection, personalize treatment modalities thereby improving overall results for men.
The treatment choices for male breast cancers have historically been identical to those applied to their female counterparts such as surgery, chemotherapy, radiation therapy or hormone therapy. Nonetheless, there is ongoing research that aims at developing customized therapeutic approaches which take into account distinctive characteristics exhibited by male breast cancers from their female types. Clinical trials play a crucial role in testing new drugs and strategies specifically designed for males aimed at enhancing better chances of survival and improved quality life expectancies.
Awareness campaigns against stigmatization surrounding men’s breast cancer are also gaining momentum in the male breast cancer marketing field calling for frequent screenings thus removing stigma around it. It goes without saying that public health initiatives coupled with educational programs should be employed so that early detection can occur; this greatly determines how successful treatment could turn out to be if done at an earlier stage rather than later when it would be too late to begin any intervention. Furthermore, client-based care networks have come up specifically meant for males having breasts suffering from this killer disease assisting them emotionally during treatment as a form community away from home.
A limited understanding regarding the pathogenesis behind this disease and considered as orphan diseases is a challenge to the male breast cancer market. It becomes difficult to develop targeted therapies because there are no comprehensive data sets, or large-scale clinical trials in rare cases of male breast cancer. Addressing these problems will require collaboration among healthcare professionals, researchers, and policymakers to focus on research for male breast cancer and allocate resources accordingly.
The evolving nature of the market for male breast cancer has seen an increased realization that what is needed goes beyond mere medication. This means not only improved medical treatments but also psychological well-being and emotional support received by such patients. The integration of psychosocial care into the male breast cancer treatment paradigm can greatly enhance the overall wellbeing and resilience of patients.
Male Breast Cancer Market Size was valued at USD 1.43 Billion in 2023. The Global Male Breast Cancer industry is projected to grow from USD 1.82 Billion in 2024 to USD 4.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.27% during the forecast period (2024 - 2032).
Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
The male breast cancer market has been segmented into type, cancer diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
Some of the key players in the male breast cancer market are:
Geographically, the Americas is anticipated to dominate the male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833.
Europe is expected to hold the second largest position in the male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.
Male Breast Cancer Market, by Type
Male Breast Cancer Market, by Diagnosis
Male Breast Cancer Market, by Treatment
BY Treatment
Male Breast Cancer Market, by Region
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)